BioXcel Therapeutics, Inc. (BTAI) intrinsic value & 10-year financials
BioXcel Therapeutics, Inc. (BTAI) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 9 fiscal years revenue grew 19.6% a year to $642.0K, with an average return on invested capital of 735.7%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- $642.0K
- Revenue growth (9-yr CAGR)
- 19.6%
- ROIC (10-yr avg)
- 735.7%
- Free cash flow (FY2025)
- -$57.6M
BTAI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $642.0K | -$69.9M | -$5.73 | -$57.6M | -7860.0% | 291.1% |
| FY2024 | $2.3M | -$59.6M | -$4.70 | -$72.0M | -2967.6% | 327.4% |
| FY2023 | $1.4M | -$179.1M | -$1.23 | -$155.0M | -12448.0% | 784.3% |
| FY2022 | $375.0K | -$165.8M | -$1.18 | -$135.5M | -42572.0% | 995.3% |
| FY2021 | — | -$106.9M | -$0.81 | -$82.6M | — | 1405.0% |
| FY2020 | — | -$82.2M | -$0.76 | -$66.7M | — | 1725.0% |
| FY2019 | — | -$33.0M | — | -$28.1M | — | 732.3% |
| FY2018 | — | -$19.3M | — | -$13.8M | — | -101.7% |
| FY2017 | — | -$4.5M | — | — | — | 462.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BioXcel Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
BioXcel Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -3.8% ROIC.
BioXcel Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, BioXcel Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-190.33 per share.